#	Pagina
attuale pagina	/open-h2020/projects/221843/index.html
-1	/open-h2020/projects/227538/index.html
-2	/open-h2020/projects/212478/index.html
-3	/open-h2020/projects/197530/index.html
-4	/open-h2020/per-topic/smartantennatech/list/index.html
-5	/open-h2020/projects/212943/results.html
-6	/open-h2020/projects/194948/index.html
-7	/open-h2020/projects/223923/index.html
-8	/open-h2020/per-topic/multipartite/list/index.html
-9	/open-h2020/projects/212512/index.html
-10	/open-h2020/projects/221812/index.html

Opendata, web and dolomites

TRAIN-HEART SIGNED

TRAIN-HEART

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

TRAIN-HEART project word cloud

Explore the words cloud of the TRAIN-HEART project. It provides you a very rough idea of what is the project "TRAIN-HEART" about.

chemically right biology innovative underlying therapies causes insights skills modified employability promise tissue complemented treating league therapeutic multidisciplinary entrepreneurial treatment envisioned combination efficacy harness detrimental molecules heart substantially micrornas trainings rnas keen specialised individual intersectoral synergies provides phd accelerate train rna ischemic horizons curative excellent generation pathogenesis science fellows act teams oligonucleotides cutting edge therapy brings transferable scientific momentous arrangements training critical therapeutics active hold network companies stress cardiac cardiovascular coding academic biotech international encourage supervision tolerability clinic remodelling transplantation chronic exception expand drug proposition 15 functional content strategies minded innovation disease genomics specificity regulators

Project "TRAIN-HEART" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITEIT MAASTRICHT Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD website: http://www.maastrichtuniversity.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	3˙940˙388 €
EC max contribution	3˙940˙388 € (100%)
Programme	1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
Code Call	H2020-MSCA-ITN-2018
Funding Scheme	MSCA-ITN-ETN
Starting year	2019
Duration (year-month-day)	from 2019-06-01 to 2023-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITEIT MAASTRICHT UNIVERSITEIT MAASTRICHT Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD website: http://www.maastrichtuniversity.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	coordinator	531˙239.00
2	KING'S COLLEGE LONDON KING'S COLLEGE LONDON Organization address address: STRAND city: LONDON postcode: WC2R 2LS website: www.kcl.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	606˙345.00
3	HUMANITAS MIRASOLE SPA HUMANITAS MIRASOLE SPA Organization address address: VIA MANZONI 56 city: ROZZANO (MI) postcode: 20100 website: www.humanitas.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROZZANO (MI))	participant	522˙999.00
4	TECHNISCHE UNIVERSITAET MUENCHEN TECHNISCHE UNIVERSITAET MUENCHEN Organization address address: Arcisstrasse 21 city: MUENCHEN postcode: 80333 website: www.tu-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	505˙576.00
5	UNIVERSIDADE DO PORTO UNIVERSIDADE DO PORTO Organization address address: PRACA GOMES TEIXEIRA city: PORTO postcode: 4099 002 website: http://www.up.pt contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (PORTO)	participant	475˙440.00
6	UNIVERSITE LYON 1 CLAUDE BERNARD UNIVERSITE LYON 1 CLAUDE BERNARD Organization address address: BOULEVARD DU 11 NOVEMBRE 1918 NUM43 city: VILLEURBANNE CEDEX postcode: 69622 website: www.univ-Iyon1.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (VILLEURBANNE CEDEX)	participant	274˙802.00
7	MIRABILIS THERAPEUTICS BV MIRABILIS THERAPEUTICS BV Organization address address: OXFORDLAAN 70 city: MAASTRICHT postcode: 6229 EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	participant	265˙619.00
8	MEDIZINISCHE HOCHSCHULE HANNOVER MEDIZINISCHE HOCHSCHULE HANNOVER Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 website: www.mh-hannover.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	participant	252˙788.00
9	MILTENYI BIOTEC GMBH MILTENYI BIOTEC GMBH Organization address address: FRIEDRICH EBERT STRASSE 68 city: BERGISH GLADBACH postcode: 51429 website: www.miltenyibiotec.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERGISH GLADBACH)	participant	252˙788.00
10	UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF Organization address address: Martinistrasse 52 city: HAMBURG postcode: 20251 website: www.uke.uni-hamburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	252˙788.00
11	ACCELERO BIOANALYTICS GMBH ACCELERO BIOANALYTICS GMBH Organization address address: SCHULZESTRASSE 20 city: BERLIN postcode: 13187 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	partner	0.00
12	DESCIN BV DESCIN BV Organization address address: CONICKSMEER 2 city: Vinkeveen postcode: 3645WG website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Vinkeveen)	partner	0.00
13	EHT TECHNOLOGIES GMBH EHT TECHNOLOGIES GMBH Organization address address: MARTINISTRASSE 52, C/O INSTITUT FUR EXPERIMENTELLE MAKOLOGIE UND TOXIKOLOGIE, UNIVERSITATSK LINIKUM, HAMBURG-EPPENDORF city: HAMBURG postcode: 20246 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	partner	0.00
14	HARTERAAD HARTERAAD Organization address address: PRINSES CATHARINA-AMALIASTRAAT 10 city: S-GRAVENHAGE postcode: 2496 XD website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (S-GRAVENHAGE)	partner	0.00
15	KANEKA EUROGENTEC KANEKA EUROGENTEC Organization address address: RUE DU BOIS SAINT-JEAN 5 city: SERAING postcode: 4102 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (SERAING)	partner	0.00
16	SOCIETE EUROPEENNE DE CARDIOLOGIE SOCIETE EUROPEENNE DE CARDIOLOGIE Organization address address: ROUTE DES COLLES 2035 city: BIOT SOPHIA ANTIPOLIS postcode: 6903 website: www.escardio.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (BIOT SOPHIA ANTIPOLIS)	partner	0.00

Map

Project objective

TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics for the treatment of ischemic heart failure. Under chronic cardiac stress, non-coding RNAs, in particular microRNAs and long non-coding RNAs, act as critical regulators of cardiac tissue remodelling. Innovative therapies targeting these RNA molecules hold great promise in treating the underlying causes of ischemic heart failure. With the exception of heart transplantation, there is no curative therapy available for this detrimental disease. Given the challenges related to delivery, specificity and tolerability of RNA therapeutics, developments in chemically modified oligonucleotides and drug delivery strategies are growing substantially. TRAIN-HEART’s proposition is to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems. TRAIN-HEART provides such training in a European network of top-level academic teams and (biotech) companies active in the fields of cardiovascular biology, functional genomics and drug development. All individual research projects demonstrate multidisciplinary content and supervision arrangements, momentous intersectoral exchanges and international synergies. These PhD programmes are complemented with the right combination of specialised research- and transferable skills trainings to encourage excellent science, innovation and long-term employability. The TRAIN-HEART fellows are envisioned to become entrepreneurial researchers who are keen to bring cutting-edge scientific concepts in RNA therapeutics to the clinic.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRAIN-HEART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRAIN-HEART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More

ARCH (2019)

AGE-RELATED CHANGES IN HEMATOPOIESIS

Read More